उत्पाद विवरण
Canmab 440 mg Injection is a targeted therapy designed for individuals battling metastatic breast cancer and metastatic gastric cancer. This innovative treatment is classified as a monoclonal antibody, specifically engineered to inhibit the HER2/neu receptor, which plays a crucial role in the growth and spread of certain cancer cells. By binding to these receptors on the surface of tumor cells, Canmab effectively disrupts their proliferation, ultimately slowing down the advancement of the disease. Patients receiving Canmab should be aware of potential side effects, including fatigue, nausea, and infusion-related reactions, which can occur during treatment. It is essential for healthcare providers to monitor patients closely for any adverse reactions and to discuss the benefits and risks associated with this therapy. As a vital option in the oncology landscape, Canmab 440 mg Injection not only offers hope but also represents a significant advancement in personalized cancer care. For those diagnosed with HER2-positive cancers, this medication may provide a vital lifeline in their treatment journey. Always consult with a healthcare professional to determine the most appropriate treatment plan tailored to individual needs.
Send Email 
जांच भेजें
जांच भेजें
एसएमएस भेजें
English
Spanish
French
German
Italian
Chinese (Simplified)
Japanese
Korean
Arabic
Portuguese